Article info

Download PDFPDF

164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy
Free

Authors

Citation

Lorusso D, Vergote I, Oaknin A, et al
164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

Publication history

  • First published October 12, 2021.
Online issue publication 
October 12, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.